Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $4.83.
A number of analysts have recently issued reports on CLSD shares. Oppenheimer started coverage on Clearside Biomedical in a report on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 price target on shares of Clearside Biomedical in a research report on Tuesday, August 13th. Chardan Capital initiated coverage on shares of Clearside Biomedical in a research report on Wednesday, August 21st. They set a “buy” rating and a $6.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Clearside Biomedical in a research report on Tuesday, August 27th.
View Our Latest Analysis on Clearside Biomedical
Clearside Biomedical Price Performance
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.25 million. During the same quarter last year, the company posted ($0.15) EPS. Equities analysts expect that Clearside Biomedical will post -0.56 EPS for the current fiscal year.
Hedge Funds Weigh In On Clearside Biomedical
A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Clearside Biomedical by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock worth $3,811,000 after purchasing an additional 314,480 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Clearside Biomedical during the 2nd quarter worth $368,000. International Assets Investment Management LLC acquired a new position in shares of Clearside Biomedical in the 1st quarter valued at $57,000. Renaissance Technologies LLC increased its holdings in Clearside Biomedical by 6.6% in the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock valued at $757,000 after purchasing an additional 35,900 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in Clearside Biomedical by 172.2% during the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock worth $71,000 after buying an additional 34,359 shares during the last quarter. 18.75% of the stock is owned by institutional investors.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
- Five stocks we like better than Clearside Biomedical
- Consumer Staples Stocks, Explained
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Which Wall Street Analysts are the Most Accurate?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Using the MarketBeat Stock Split Calculator
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.